APYX
Apyx Medical Corporation
APYX's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over APYX overall, supported by lower modeled downside and stronger fundamentals.
APYX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Unavailable |
APYX's revenue is currently healthy, and its profitability is stable, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
APYX PE Valuation
APYX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
APYX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect APYX's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
APYX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.19 | +$0.18 |
| Q2 2026 | -$0.20 | +$0.26 |
| Q1 2026 | -$0.22 | +$0.34 |
| Q4 2025 | -$0.27 | +$0.41 |
| Q3 2025 | -$0.37 | +$0.46 |
| Q2 2025 | -$0.46 | +$0.36 |
| Q1 2025 | -$0.56 | +$0.10 |
| Q4 2024 | -$0.68 | -$0.14 |
APYX is still losing money, but far less than before: $0.19 per share over the past year, against $0.83 at its worst in late 2024.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over APYX on earnings quality, reporting a profit while its opponent remains loss making.
APYX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $14M | +9% |
| Q2 2026 | $13.9M | +22% |
| Q1 2026 | $12.5M | +32% |
| Q4 2025 | $19.2M | +35% |
| Q3 2025 | $12.9M | +12% |
| Q2 2025 | $11.4M | -6.4% |
| Q1 2025 | $9.4M | -7.9% |
| Q4 2024 | $14.2M | -3% |
APYX's revenue has grown year over year for five quarters in a row: $14M last quarter, up 9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4.1% | +2.4 points |
| Q2 2026 | -13% | +9.6 points |
| Q1 2026 | -7.3% | +25 points |
| Q4 2025 | 0.1% | +22 points |
| Q3 2025 | -6.5% | +25 points |
| Q2 2025 | -23% | +23 points |
| Q1 2025 | -32% | +32 points |
| Q4 2024 | -21% | +18 points |
APYX's operating margin was −4.1% last quarter, up 2.4 points from the same quarter a year ago, near the top of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over APYX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over APYX on profitability, with a higher operating margin.
APYX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.9M | +$2.2M |
| Q2 2026 | -$3.6M | -$2.1M |
| Q1 2026 | -$632K | +$125K |
| Q4 2025 | -$2.8M | +$377K |
| Q3 2025 | -$4.1M | +$538K |
| Q2 2025 | -$1.5M | +$3.1M |
| Q1 2025 | -$757K | +$5.6M |
| Q4 2024 | -$3.2M | -$877K |
APYX has burned cash in almost every quarter: −$9M over the past year, against −$9M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over APYX on cash generation, producing positive trailing cash flow while its opponent burns cash.
APYX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +195K shares |
| 1 year | +8.1% | +3.3M shares |
| 3 years | +27% | +9.4M shares |
| 5 years | +28% | +9.7M shares |
| Available history | +29% | +10M shares |
APYX has 44M diluted shares, up 8.1% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over APYX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
APYX Net Leverage
APYX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
APYX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.3 | Neutral |
| Stochastic | 28.7 | Neutral |
APYX's weekly RSI is 44 (neutral) and its Stochastic is 29 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
APYX PE vs Healthcare Sector
APYX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
APYX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.68 | 7.8% above |
| 20 week MA | $3.24 | 11% below |
| 50 week MA | $3.58 | 19% below |
| 100 week MA | $2.77 | 4.3% above |
| 200 week MA | $2.73 | 5.9% above |
APYX's trend is mixed: it's above three of its five weekly moving averages, and 5.9% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over APYX on trend strength, trading above more of its moving averages.
APYX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.23 | $7.04 | -14% |
| 2021 | $7.04 | $13.1 | +86% |
| 2022 | $13.1 | $1.99 | -85% |
| 2023 | $1.99 | $2.62 | +32% |
| 2024 | $2.62 | $1.64 | -37% |
| 2025 | $1.64 | $3.44 | +110% |
| 2026 YTD | $3.44 | $2.89 | -16% |
APYX's yearly returns have swung widely, from +110% in 2025 to −85% in 2022. It's down 16% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over APYX on returns for 2026, with the stronger performance.